peptide wiki

Melanotan II

aka MT-2

Melanocortin

Mechanism

Melanotan II (MT-II) is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 — developed at the University of Arizona in the 1980s by Hruby, Hadley, and colleagues as a candidate photoprotection / sunless-tanning agent. It has never been approved by the FDA or any other regulator for any indication; clinical development was abandoned and it is sold only via grey-market research-chemical channels. Genuine safety signals have been reported, including darkening of existing moles, eruptive atypical nevi, and case reports of new primary melanoma in young tanning-seeking users.

Identification

CAS number121062-08-6
Molecular formulaC50H69N15O9
SequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
Typical dose0.25–0.5 mg/day subcutaneous (loading); Phase I clinical starting dose 0.01 mg/kg/day SC
Half-life~30–60 minutes

Vendors selling Melanotan II

VendorSizePriceListed purityTrust
Moglabs 10 mg $28.00 96
Moglabs 10 mg $38.00 96
Crush Research 10 mg $43.00 95
Orbitrex Peptides $39.99 95
Profound Aminos 10 mg $59.00 95
Prime Peptides 10 mg $40.00 95
Peptide Tech 10 mg $34.99 94
Amino Club $29.99 93
Skye Peptides 12.5 mg $49.00 90
Peptide Plugs 10 mg $40.00 89
EZ Peptides 10 mg $44.00 85
Simple Peptide $38.00 85
Peptidegurus 10 mg 84
Peptidegurus 10 mg 84
Peptidegurus 20 mg 84
Peptidegurus 30 mg 84
Ascension Peptides 10 mg $43.00 84
Cocer Peptides 10 mg $60.00 82
Texpeptide 10 mg $40.00 70
Crystal Peptides 10 mg $34.99 66
Mandy 10 mg $41.00 43
MJT peptides 10 mg $51.00 39
HK Peptide Ltd (hk peptides) 37
Cernum Biosciences 10 mg $44.99
NG Peptide 10 mg $24.99
Alpha Omega 10 mg $38.00
Bulk Peptides 10 mg $140.00
Felix Chemical Supply 10 mg $29.99
Ignite Peptides 10 mg $40.00
Kimera Chems $41.99
Oneday Compounds 10 mg $44.99
Pepvida Labs 10 mg $35.00
Polaris Peptides 17 mg $45.00
Soma Peptides $69.00
Soma Peptides 10 mg $49.00
Southern Aminos 10 mg $36.75
True Peptide 10 mg $28.00
Wellness Peptides $45.00

Research

Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report
Bonchev A. · Life (Basel, Switzerland) (2026) · case-report

This case report presents a three-month follow-up of a patient who self-administered Melanotan II injections over a period of 64 days with the goal of achieving a deeper tanning effect. Melanotan II is an unlicensed synthetic peptide analog belonging to the melanocortin hormone family.

source →
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
· ClinicalTrials.gov (2026) · rct

This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo.

source →
Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?
Yassin Alsabbagh A, Bhujel N, Singh RP. · International journal of oral and maxillofacial surgery (2025) · case-report

The case of a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II, a nasal spray containing a synthetic analogue of melanocyte-stimulating hormone, is reported. The patient had used the nasal spray for tanning purposes.

source →
Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress
Inozemtseva LS, Yatsenko KA, Glazova NY, Kamensky AA, Myasoedov NF, Levitskaya NG, Grivennikov IA, Dolotov OV. · European journal of pharmacology (2024) · animal

Current antidepressant therapy shows substantial limitations, and there is an urgent need for the development of new treatment strategies for depression. Stressful events and hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis play an important role in the pathogenesis of depression.

source →
5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II
Todorovic M, Blanc A, Wang Z, Lozada J, Froelich J, Zeisler J, Zhang C, Merkens H, Benard F, Perrin DM. · Chemistry (Weinheim an der Bergstrasse, Germany) (2024) ·

With peptides increasingly favored as drugs, natural product motifs, namely the tryptathionine staple, found in amatoxins and phallotoxins, and the 2,2'-bis-indole found in staurosporine represent unexplored staples for unnatural peptide macrocycles.

source →
Melanotan-II reverses memory impairment induced by a short-term HF diet
Wekwejt P, Wojda U, Kiryk A. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2023) · animal

A high-fat (HF) diet has been shown to increase the risk of neurological impairments and neurodegenerative disorders. The melanotropins used in this study have been associated with diet-related disorders; however, there is an absence of studies on their effect on diet-induced neurobehavioral conditions.

source →
CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists
Tomassi S, Dimmito MP, Cai M, D'Aniello A, Del Bene A, Messere A, Liu Z, Zhu T, Hruby VJ, Stefanucci A, Cosconati S, Mollica A, Di Maro S. · Journal of medicinal chemistry (2022) ·

The pleiotropic role played by melanocortin receptors (MCRs) in both physiological and pathological processes has stimulated medicinal chemists to develop synthetic agonists/antagonists with improved potency and selectivity.

source →
Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food
Eliason NL, Martin L, Low MJ, Sharpe AL. · Neuropeptides (2022) · animal

Rationale Obesity is a major health problem worldwide. An understanding of the factors that drive feeding behaviors is key to the development of pharmaceuticals to decrease appetite and consumption.

source →
Melanotan II User Experience: A Qualitative Study of Online Discussion Forums
Gilhooley E, Daly S, McKenna D. · Dermatology (Basel, Switzerland) (2021) ·

Background Melanotan II (MT II) is a synthetic analogue of α-melanocyte-stimulating hormone that, via interaction with the melanocortin 1 receptor, induces skin hyperpigmentation.

source →
Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice
McMillan TR, Forster MAM, Short LI, Rudecki AP, Cline DL, Gray SL. · Experimental physiology (2021) · animal

New findings What is the central question of this study? Can chronic treatment of pituitary adenylate cyclase-activating polypeptide (PACAP) deficient mice with the melanocortin agonist melanotan II during cold acclimation rescue the impaired thermogenic capacity previously observed in PACAP deficient mice?

source →
LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs
Mestria S, Odoardi S, Frison G, Strano Rossi S. · Drug testing and analysis (2021) ·

The spread of performance and image enhancing drugs (PIEDs) often requires forensic toxicology laboratories to identify unknown compounds without reference standards.

source →
Melanotan II: a possible cause of renal infarction: review of the literature and case report
Peters B, Hadimeri H, Wahlberg R, Afghahi H. · CEN case reports (2020) · review

Renal infarction is an uncommon condition resulting from an acute disruption of renal blood flow and it is potentially life-threatening disease. The cause and outcome of renal infarction is not well established and is frequently misdiagnosed or diagnosed late.

source →
Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism
Minakova E, Lang J, Medel-Matus JS, Gould GG, Reynolds A, Shin D, Mazarati A, Sankar R. · PloS one (2019) · animal

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by impaired social interactions, difficulty with communication, and repetitive behavior patterns. In humans affected by ASD, there is a male pre-disposition towards the condition with a male to female ratio of 4:1.

source →